130 related articles for article (PubMed ID: 35585813)
1. Efficacy of Raloxifene as Add-on Therapy on Disease Activity of Postmenopausal Women with Rheumatoid Arthritis: A Double-blind, Randomized, Placebo-controlled Clinical Trial.
Sahebari M; Sarafraz Yazdi M; Mehrnaz Aghili S; Esmaily H; Saeidi S; Salari M
Curr Rheumatol Rev; 2023; 19(1):93-101. PubMed ID: 35585813
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
3. Post-menopausal women with rheumatoid arthritis who are treated with raloxifene or alendronate or glucocorticoids have lower serum undercarboxylated osteocalcin levels.
Mokuda S; Okuda Y; Onishi M; Sawada N; Matoba K; Yamada A; Jouyama K; Takasugi K
J Endocrinol Invest; 2012 Jul; 35(7):661-4. PubMed ID: 21970822
[TBL] [Abstract][Full Text] [Related]
4. Similar proportions of women lose bone mineral density with raloxifene or alendronate treatment.
Adachi JD; Adami S; Kulkarni PM; Wong M; Stock JL
J Clin Densitom; 2005; 8(3):273-7. PubMed ID: 16055956
[TBL] [Abstract][Full Text] [Related]
5. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
[TBL] [Abstract][Full Text] [Related]
6. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group.
Cummings SR; Palermo L; Browner W; Marcus R; Wallace R; Pearson J; Blackwell T; Eckert S; Black D
JAMA; 2000 Mar; 283(10):1318-21. PubMed ID: 10714731
[TBL] [Abstract][Full Text] [Related]
7. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis.
Michalská D; Stepan JJ; Basson BR; Pavo I
J Clin Endocrinol Metab; 2006 Mar; 91(3):870-7. PubMed ID: 16352692
[TBL] [Abstract][Full Text] [Related]
8. Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide.
Eastell R; Rogers A; Ni X; Krege JH
Osteoporos Int; 2011 Jun; 22(6):1927-34. PubMed ID: 20838771
[TBL] [Abstract][Full Text] [Related]
9. Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia.
Gorai I; Hattori S; Tanaka Y; Iwaoki Y
J Bone Miner Metab; 2012 May; 30(3):349-58. PubMed ID: 22130786
[TBL] [Abstract][Full Text] [Related]
10. Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis.
Tanaka M; Itoh K; Matsushita K; Matsushita K; Moriishi M; Kawanishi H; Fukagawa M
Ther Apher Dial; 2011 Jun; 15 Suppl 1():62-6. PubMed ID: 21595855
[TBL] [Abstract][Full Text] [Related]
11. Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women.
Pasion EG; Sivananthan SK; Kung AW; Chen SH; Chen YJ; Mirasol R; Tay BK; Shah GA; Khan MA; Tam F; Hall BJ; Thiebaud D
J Bone Miner Metab; 2007; 25(2):105-13. PubMed ID: 17323180
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene Prevents Early Periprosthetic Bone Loss for Postmenopausal Women after Uncemented Total Hip Arthroplasty: A Randomized Placebo-Controlled Clinical Trial.
Gong L; Zhang YY; Yang N; Qian HJ; Zhang LK; Tan MS
Orthop Surg; 2020 Aug; 12(4):1074-1083. PubMed ID: 32686337
[TBL] [Abstract][Full Text] [Related]
13. Clinical results of alendronate monotherapy and combined therapy with menatetrenone (VitK₂) in postmenopausal RA patients.
Suzuki K; Tsuji S; Fukushima Y; Nakase T; Hamada M; Tomita T; Yoshikawa H
Mod Rheumatol; 2013 May; 23(3):450-5. PubMed ID: 22692649
[TBL] [Abstract][Full Text] [Related]
14. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
[TBL] [Abstract][Full Text] [Related]
15. Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis.
Kendler DL; Palacios S; Cox DA; Stock J; Alam J; Dowsett SA; Zanchetta J
Osteoporos Int; 2012 Mar; 23(3):1091-101. PubMed ID: 21374068
[TBL] [Abstract][Full Text] [Related]
16. Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis.
Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
Yonsei Med J; 2008 Feb; 49(1):119-28. PubMed ID: 18306478
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Recker RR; Kendler D; Recknor CP; Rooney TW; Lewiecki EM; Utian WH; Cauley JA; Lorraine J; Qu Y; Kulkarni PM; Gaich CL; Wong M; Plouffe L; Stock JL
Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297
[TBL] [Abstract][Full Text] [Related]
18. Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04.
Uemura Y; Sone T; Tanaka S; Miyazaki T; Tsukiyama M; Taguchi A; Soen S; Mori S; Hagino H; Sugimoto T; Fukunaga M; Ohta H; Nakamura T; Orimo H; Shiraki M;
Curr Med Res Opin; 2020 Nov; 36(11):1847-1859. PubMed ID: 32870712
[TBL] [Abstract][Full Text] [Related]
19. Adiponectin and leptin serum levels in osteoporotic postmenopausal women treated with raloxifene or alendronate.
Sebastián-Ochoa A; Fernández-García D; Reyes-García R; Mezquita-Raya P; Rozas-Moreno P; Alonso-Garcia G; Muñoz-Torres M
Menopause; 2012 Feb; 19(2):172-7. PubMed ID: 21971209
[TBL] [Abstract][Full Text] [Related]
20. Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate.
Wermers RA; Recknor CP; Cosman F; Xie L; Glass EV; Krege JH
Osteoporos Int; 2008 Jul; 19(7):1055-65. PubMed ID: 18283386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
